Navigation Links
HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology
Date:3/21/2011

BRANFORD, Conn., March 21, 2011 /PRNewswire/ -- HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

Digital pathology involves taking digital pictures of an anatomic pathology specimen, a slide with cells or a thinly-sliced piece of tissue, and managing the interpretation and storage of the resulting images.  While most companies involved in digital pathology emphasize generation and storage of images for interpretation, HistoRx is the only company to bring reproducibility, or standardization, to those images, to quantify protein in tissue for accurate biomarker measurement.

"This patent covers HistoRx's unique ability to ensure that multiple instruments performing the same test, whether in one or many locations, can give the same result for a patient's slide," said Jason Christiansen, Senior Director of Operations at HistoRx and the lead inventor.  "We don't make digital microscopy systems, we make digital microscopy systems better."

Quantitative IHC (qIHC) is only as good as the image from which the data is derived.  Robust quantitative data can only be achieved from reproducible images, generated with information from standardized digital microscopy instruments.  HistoRx is the first company to address standardization of digital microscopy instruments to deliver high quality reproducible data that precisely relates to biomarker concentrations in tissue sections -- data that is essential to the development and delivery of personalized cancer care.

The patented approach applies to qIHC, as well as all uses of digital microscopy and establishes the definition for standardization and reproducibility in both brightfield and fluorescent digital pathology.

U.S. Patent No. 7,907,271 is the first assigned to HistoRx and is entitled "Method and System for Standardizing Microscope Instruments."  Inventors Jason Christiansen, Robert Pinard, Maciej Zerkowski and Greg Tedeschi are all current or former employees of the company.

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with any other method, digital or otherwise.  AQUA analysis is used in cancer research by twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting occurred in 2010 with the launch by Genoptix Inc. (a subsidiary of Novartis) of diagnostic tests based on AQUA technology licensed from HistoRx. AQUA technology is currently available on the ScanScope FL™ from Aperio and will be available later this year on the Nuance™ and Vectra™ systems from Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
3. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
4. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/27/2016)... , May 27, 2016 ... drug manufacturers, health insurance companies all falling under its ... healthcare companies. While not often talked about, these healthcare ... The United States is by far the ... Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. (OTC: ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... ... 26, 2016 , ... Cabot Corporation, Pfizer, and 3M are ... court documents and SEC filings. A jury has returned a verdict of ... Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
Breaking Medicine News(10 mins):